Therapy-enhancing glucan

Details Therapy-enhancing glucan Therapy-enhancing glucan

2005-08-31

2008-12-09

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S057000, C424S138100, C424S155100, C536S056000, C536S123120

Reexamination Certificate

active

07462607

ABSTRACT:
This invention provides a composition comprising an effective amount of (1-3),(1-4)-β-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject.

REFERENCES:
patent: 3975553 (1976-08-01), Griffon
patent: 3987166 (1976-10-01), Komatsu et al.
patent: 4251519 (1981-02-01), Robbins et al.
patent: 4343784 (1982-08-01), Massot et al.
patent: 4454289 (1984-06-01), Nakajima et al.
patent: 4705780 (1987-11-01), Massot et al.
patent: 4761402 (1988-08-01), Williams et al.
patent: 4818752 (1989-04-01), Williams et al.
patent: 4833131 (1989-05-01), Williams et al.
patent: 4900722 (1990-02-01), Williams et al.
patent: 4926094 (1990-05-01), Bondeson et al.
patent: 4992540 (1991-02-01), Jamas et al.
patent: 5037972 (1991-08-01), Jamas et al.
patent: 5130127 (1992-07-01), Herlyn
patent: 5189028 (1993-02-01), Nikl et al.
patent: 5532223 (1996-07-01), Jamas et al.
patent: 5576015 (1996-11-01), Donzis et al.
patent: 5607677 (1997-03-01), Jamas et al.
patent: 5622939 (1997-04-01), Jamas et al.
patent: 5622940 (1997-04-01), Ostroff et al.
patent: 5702719 (1997-12-01), Donzis et al.
patent: 5783569 (1998-07-01), Jamas et al.
patent: 5804199 (1998-09-01), Aasjord et al.
patent: 5811542 (1998-09-01), Jamas et al.
patent: 5817643 (1998-10-01), Jamas et al.
patent: 5849720 (1998-12-01), Jamas et al.
patent: 5980918 (1999-11-01), Klein
patent: 6020324 (2000-02-01), Jamas et al.
patent: 6117850 (2000-09-01), Patchen et al.
patent: 6143731 (2000-11-01), Jamas et al.
patent: 6143883 (2000-11-01), Lehmann et al.
patent: 6573245 (2003-06-01), Marciani
patent: 6664370 (2003-12-01), Cheever et al.
patent: 7030101 (2006-04-01), Pavliak et al.
patent: 7070778 (2006-07-01), Yvin et al.
patent: 2002/0044919 (2002-04-01), Yu
patent: 2002/0119928 (2002-08-01), McAnalley et al.
patent: 2003/0180254 (2003-09-01), Lane et al.
patent: 2004/0109857 (2004-06-01), Chu et al.
patent: 2004/0248772 (2004-12-01), Yagita
patent: 2004/0266726 (2004-12-01), Yagita
patent: 2005/0118187 (2005-06-01), Yu
patent: 2005/0208079 (2005-09-01), Cassone et al.
patent: 2006/0009419 (2006-01-01), Ross
patent: 2006/0020128 (2006-01-01), Cheung
patent: 2006/0165700 (2006-07-01), Ostroff et al.
patent: 2006/0188506 (2006-08-01), Cheung
patent: 2006/0263355 (2006-11-01), Quan et al.
patent: 2007/0020232 (2007-01-01), Rossignol et al.
patent: 2007/0059310 (2007-03-01), Karel
patent: 2007/0134259 (2007-06-01), Bundle et al.
patent: 3019614 (1981-12-01), None
patent: 0 194 851 (1986-09-01), None
patent: 0194851 (1986-09-01), None
patent: 0463540 (1992-02-01), None
patent: 62252730 (1987-04-01), None
patent: 63307825 (1988-12-01), None
patent: WO 9103248 (1991-03-01), None
patent: WO 98/39013 (1998-09-01), None
patent: WO 99/52548 (1999-10-01), None
patent: WO 00/15238 (2000-03-01), None
patent: WO 01/62283 (2001-08-01), None
patent: WO 0168105 (2001-09-01), None
patent: WO 0180807 (2001-11-01), None
patent: WO 02058711 (2002-08-01), None
patent: WO 03004507 (2003-01-01), None
patent: WO 2004/014320 (2004-02-01), None
patent: WO 2004/014320 (2004-02-01), None
patent: WO 2004/021994 (2004-03-01), None
patent: WO 2004/021994 (2004-03-01), None
patent: WO 2004030613 (2004-04-01), None
patent: WO 2005027936 (2005-03-01), None
patent: WO 2005027938 (2005-03-01), None
patent: WO 2005049044 (2005-06-01), None
patent: WO 2006085895 (2006-08-01), None
patent: WO 2006119395 (2006-11-01), None
patent: WO 03/54077 (2007-07-01), None
patent: WO 2007084661 (2007-07-01), None
Yan et al. “B-glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3,” Journal of Immunology, 1999, vol. 163, pp. 3045-3052.
Basic and Clinical Pharmacology, 7th edition, 1998, Bertram G. Katzung, pp. 881-884.
U.S. Appl. No. 10/565,484, filed Jan. 2006, Cheung.
U.S. Appl. No. 11/334,763, filed Jan. 2006, Cheung.
Yan et al., “Beta-Glucan, a ‘Specific’ Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)” Journal of Immunology (1999) vol. 163, pp. 3045-3052.
Herrera et al. “Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro” Leukemia (2000) vol. 14, pp. 853-858.
Onizuka et al. “Tumor Rejection by in vivo Administration od Anti-CD25 (Interleukin-2 Receptor alpha) Monoclonal Antibody” Cancer Research (1999) vol. 59, pp. 3128-3133.
Rai et al. “Monoclonal Antibodies in Chronic Lymphocytic Leukemia” Review of Clinical Experimental Hematology, vol. 4, Issue 2, pp. 134-144.
The Merck Manual of Diagnosis and Therapy, seventeenth edition, 1999, Published by Merck Research Laboratories, pp. 397-398, 948-949, 1916, and 1979-1981.
The Oxford Textbook of Oncology, 1995, published by Oxford University Press, pp. 447-453.
Ohno et al., “Antitumor 1,3-beta-glucan form Cultured Fruit Body ofSparassis crispa” Biological and Pharmaceutical Bulletin (2000) vol. 23, No. 7, pp. 866-872.
Nanba et al. “Antitumor Mechanisms of Orally Administered Shiitake Fruit Bodies” Chemical and Pharmaceutical Bulletin (1987) vol. 38, No. 6, pp. 2459-2464.
Harada et al. “Oral Administration of PSK can Improve the Impaired Anti-Tumor CD4+ T-Cell Response in Gut-Associated Lymphoid Tissue (GALT) of Specific-Pathogen-Free Mice” International Journal of Cancer (1997) vol. 70, pp. 362-372.
Nanba et al. “Antitumor Action of Shiitake (Lentinus edodes) Fruit Bodies Orally Administered to Mice” Chemical and Pharmaceutical Bulletin (1987) vol. 35 No. 6, pp. 2453-2458.
Maloney et al., “IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma” Blood (1997) vol. 90, No. 6, pp. 2188-2195.
Bergman et al. “Treatment of Neoplastic Meningeal Xenografts by Intraventricular Administration of an Antiganglioside Monoclonal Antibody, 3F8” International Journal of Cancer (1999) vol. 82, pp. 538-548.
Capurro ey al. “FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizedLewisx hapten” Cancer Immunology and Immunotherapy (1998) vol. 45, pp. 334-339.
Soiffer et al., “Administration of R24 Monoclonal Antibody and Low-Dose Interleukin 2 for Malignant Melanoma” Clinical Cancer Research (1997) vol. 3, pp. 17-24.
Ren et al., “Mechanisms of Anti-Lung Cancer Activity for Monoclonal Antibody to Epidermal Growth Factor Receptor” Disi Junyi Daxue Xuebao (1997) vol. 18, No. 6, pp. 560-562 (abstract only).
D'Amico et al. “Molecular Biologic Substaging of Stage I Lung Cancer According to Gender and Histology” Annals of Thoracic Surgery (2000) vol. 69, pp. 882-886.
Mendelsohn et al., “Monoclonal Antibodies Against the Receptor for Epidermal Growth Factor as Potential Anticancer Agents” Cellular and Molecular Biology of Tumors and Potential Clinical Applications (1988) pp. 307-312.
Nanba et al., “Effect of Maitake D-Fraction on Cancer Prevention” Annals of the New York Academy of Sciences (1997) vol. 833, pp. 204-207.
Hong et al. Mechanism by Which Orally Administered B-1, 3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models. The Journal of Immunology. (2004) p. 797-806.
PCT International Search Report, dated Jun. 5, 2002, for Sloan-Kettering Institute for Cancer Research, PCT/US02/01276, Therapy-Enhacing Glucan.
PCT International Preliminary Examination Report, dated Mar. 27, 2003, for Sloan-Kettering Institute for Cancer Research, PCT/US02/01276, Therapy-Enhancing Glucan.
Ross, et al. Therapeutic Intervention with complement and beta-glucan in cancer, Immunopharma

Affiliated with

Also associated with

Rating

Therapy-enhancing glucan does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy-enhancing glucan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy-enhancing glucan will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4045829